Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide (2022)
Sequence: YGRKKRRQRRR
| Experiment Id | EXP000614 |
|---|---|
| Paper | Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide |
| Peptide | TAT |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | 100–400 nM (protein) |
| Rna Concentration | 100–200 nM |
| Mixing Ratio | 4:1 (RBD:siRNA) or 1:1 (Ago2:siRNA) |
| Formulation Format | protein–siRNA complex |
| Formulation Components | TAT-S19-Ago2 |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | HeLa, LNCaP |
| Animal Model | |
| Administration Route | |
| Output Type | gene knockdown |
| Output Value | Significant mRNA reduction |
| Output Units | |
| Output Notes | Rapid and efficient AR knockdown; faster than lipofection |
| Toxicity Notes | Not significant |
| Curation Notes |